Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data [Yahoo! Finance]
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Yahoo! Finance
Japan's Ministry of Health, Labour and Welfare/MHLW granted Orphan Drug designation for its investigational therapeutic, DYNE-251. This designation is for individuals with Duchenne muscular dystrophy/DMD who have mutations in the DMD gene amenable to exon 51 skipping. The company's Chief Medical Officer, Doug Kerr, highlighted that data from the ongoing DELIVER trial showed unprecedented and sustained functional improvement through 18 months, driven by significant dystrophin expression. Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data DYNE-251 is being evaluated in the global, randomized, placebo-controlled, double-blind Phase 1/2 DELIVER clinical trial. The Orphan Drug designation in Japan is for drugs treating rare diseases affecting fewer than 50,000 patients and with a high medical need. Dyne Therapeutics Inc. (NASDAQ:DYN) is a clinical-stage neuromuscular disease company that discovers and develops therapeutics for neuromuscul
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a "market perform" rating on the stock.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.MarketBeat
DYN
Earnings
- 5/8/25 - Miss
DYN
Sec Filings
- 12/5/25 - Form 144
- 12/5/25 - Form 144
- 12/5/25 - Form 4
- DYN's page on the SEC website